###### Strengths and limitations of this study

-   A comprehensive literature search was used to retrieve the published evidence, applying stringent inclusion criteria and assessed the methodological quality of the studies systematically.

-   The primary studies found had low methodological quality and level of reporting. All but one of included studies used diagnostic case--control designs.

-   The summary estimates from the exploratory meta-analysis need to be interpreted very cautiously.

-   We were unable to test all but one of the apps that had been assessed in this review because they were unavailable in the stores, and thus lack first-hand experience.

Introduction {#s1}
============

Within recent years, the number, awareness and popularity of mobile health applications (apps) have increased substantially.[@R1] Currently, over 165 000 apps covering a medical topic are available on the two largest mobile platforms Android and iOS, 9% of them addressing topics of screening, diagnosis and monitoring of various illnesses.[@R3] Also, the Medical Subject Heading (MeSH) term 'Mobile Applications' that was introduced in MEDLINE in 2014 is currently indexing approximately 1000 records.[@R4] However, while some authors predicted that mobile health apps will be the game changer of the 21st century, others pointed out that the scientific basis of mobile health apps remains thin.[@R5]

While information used for personal healthcare is traditionally captured via self-report surveys and doctor consultations, mobile devices with embedded sensors offer opportunities to entertain a continued exchange of information between patients and physicians. This dialogue is of particular importance for patients with chronic illnesses.

Three recent reviews focused on the efficacy, effectiveness and usability of mobile health apps in different clinical areas.[@R7] They did not find reasonably sized randomised trials and called for a staged process in the scientific evaluation of mobile health apps. To date, rigorous evidence syntheses of diagnostic studies are missing. In view of the fact that most apps target at a diagnostic problem, it would be helpful to gauge the scientific basis of them. In this comprehensive systematic review, we thus summarised the currently available papers assessing diagnostic properties of mobile health apps.

Methods {#s2}
=======

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses[@R10] statement recommendations.

Data sources {#s2a}
------------

Electronic searches were performed without any language restriction on MEDLINE (PubMed interface), Scopus (both databases from inception until 15 December 2016) and Web of Science inclusive Medical Informatics and Business Source Premier (by citation of reference). The full search algorithm is provided in the online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}.
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Study selection {#s2b}
---------------

We applied the PICOS format as follows: We included all studies examining subjects in a clinical setting (P) and investigating a health app that used inbuilt sensors of a smartphone (I) for diagnosis of an illness. Minimum requirement to be included in an exploratory meta-analysis was the availability of original data and the possibility to construct a two-by-two table, that is, the possibility to calculate sensitivity and specificity (O). We accepted all reference tests (C) used in these studies to classify presence or absence of disease. No selection on study design was made (S).

We excluded all studies examining apps providing psychological assessments, questionnaires or mobile alternatives of paper-based tests. We further excluded apps using external sensors, such as clip-on lenses, for the diagnostic assessment or studies, where the app was only used as the transmitter of data.

Data extraction and quality assessment {#s2c}
--------------------------------------

The methodological quality of all 11 studies[@R11] providing 2×2 table data that were summarised in the meta-analysis was made using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Reporting quality was assessed using the  'STAndards for the Reporting of Diagnostic accuracy studies\' (STARD) statement.[@R22] Quality assessment involved scrutinising the methods of data collection (prospective, retrospective) and patient selection (consecutive enrolment, convenience sample) and descriptions of the test (the type of test and analysis performed by the app) and the reference standard (method to rule-in or rule-out the illness).

Two reviewers independently assessed papers and extracted data using a standardised form. Discrepancies were resolved by discussion between the two reviewers by correspondence with study authors or arbitration by a third reviewer. This was necessary in five cases.

Apps of included studies were searched in Apple's App Store and on Google Play.

Data synthesis and analysis {#s2d}
---------------------------

Data to fill the two-by-two table were extracted of each study, and sensitivity and specificity were calculated. Sensitivity and specificity were pooled with the unified method implemented into Stata V.14.2 under the routine 'metandi'. Metandi fits a two-level mixed logistic regression model, with independent binomial distributions for the true positives and true negatives within each study and a bivariate normal model for the logit transforms of sensitivity and specificity between studies. For pooling, at least four studies on the same target condition had to be available.[@R24] Therefore, no separate analysis for health apps on Parkinson's disease, falling in patients with chronic stroke and atrial fibrillation was possible.

All analyses were done using Stata V.14.2 statistics software package.

Results {#s3}
=======

Study selection {#s3a}
---------------

Electronic searches retrieved 4010 records. After excluding duplicates, 3296 records remained and were screened based on title and abstract. Subsequently, 3209 studies were excluded because they did not fulfil the eligibility criteria. The large majority of records were excluded because they did not contain original data but expressed personal opinion about the possible role of medical smartphone apps. Eighty-seven articles were finally retrieved and read in full text to be considered for inclusion. Out of these, 30 studies provided some clinical data.[@R2] Details on these studies are available in the online [supplementary appendix 2](#SP2){ref-type="supplementary-material"}. Eleven studies reporting 17 two-by-two tables were considered in this review.[@R11] Details of these studies are available in [table 1](#T1){ref-type="table"}. The study selection process is outlined in [figure 1](#F1){ref-type="fig"}.
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###### 

Characteristics of included studies

  First author's name and year of publication   Target disease                             Design                           Consecutive enrolment   n      Average age (SD)   \% Female        Inclusion criteria                                                                                                                          Exclusion criteria
  --------------------------------------------- ------------------------------------------ -------------------------------- ----------------------- ------ ------------------ ---------------- ------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Arora *et al*[@R21] 2014                      Parkinson's disease                        Diagnostic case--control study   No                      10     65.1 (9.8)         Not reported     Not reported                                                                                                                                Other Parkinsonian or tremor disorders
  Arora *et al*[@R11] 2015                      Parkinson's disease                        Diagnostic case--control study   No                      10     65.1 (9.8)         30%              Not reported                                                                                                                                Not reported
  Chadwick *et al*[@R12] 2014                   Melanoma                                   Diagnostic case--control study   No                      15     Not applicable     Not applicable   Not reported                                                                                                                                Not reported
  Kostikis *et al*[@R13] 2015                   Parkinson's disease                        Diagnostic case--control study   No                      23     78                 52%              Not reported                                                                                                                                Not reported
  Lagido *et al*[@R14] 2014                     Atrial fibrillation                        Prospective cohort study         No                      43     Not reported       Not reported     Not reported                                                                                                                                Not reported
  Maier *et al*[@R15] 2015                      Melanoma                                   Diagnostic case--control study   Yes                     195    Not applicable     Not applicable   Not reported                                                                                                                                Quality images, other elements in the image not belonging to the lesion, for example, hair, images containing more than one lesion, incomplete imaged lesions, non-melanocytic lesions and two-point differences cases.
  Ramlakhan *et al*[@R16] 2011                  Melanoma                                   Diagnostic case--control study   No                      46     Not applicable     Not applicable   Not reported                                                                                                                                Not reported
  Takuya *et al*[@R20] 2015                     Falling in patients with chronic stroke    Diagnostic case--control study   No                      11     70.5 (12.5)        Not reported     More than 12 months since stroke onset and ability to walk 16 metres independently with or without a single-point cane and/or an orthosis   Severe cardiovascular, respiratory, musculoskeletal or neurological disorder other than stroke that affected gait performance; unable to understand the instructions because of communication problem or moderate to severe cognitive dysfunction (ie, five or more errors on the SPMSQ; household ambulators walked only indoors or only mobilised during rehabilitation sessions
  Wadhawan *et al*[@R17] 2011                   Melanoma                                   Diagnostic case--control study   No                      1300   Not applicable     Not applicable   Not reported                                                                                                                                Image artefacts
  Wadhawan *et al*[@R17] 2011                   Melanoma                                   Diagnostic case--control study   No                      347    Not applicable     Not applicable   Not reported                                                                                                                                Image artefacts
  Wolf *et al*[@R19] 2013                       Melanoma                                   Diagnostic case--control study   No                      188    Not applicable     Not applicable   Images for which there was a clear histological diagnosis rendered by a board-certified pathologist                                         Images containing identifiable features such as facial features, tattoos or labels with patient information. Lesions with equivocal diagnoses such as 'melanoma cannot be ruled out' or 'atypical melanocytic proliferation', Spitz nevi, pigmented spindle cell nevus of Reed and other uncommon or equivocal lesions, lesions with moderate or high-grade atypia poor quality or resolution of images

SPMSQ, Short Portable Mental Status Questionnaire.

![Flow chart according to the PRISMA statement. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.](bmjopen-2017-018280f01){#F1}

Study characteristics {#s3b}
---------------------

The 30 papers providing some clinical data 35 diagnostic health apps for various clinical conditions: They included: screening for melanoma (n=8),[@R12] Parkinson's disease monitoring (n=6)[@R11] tremor in Parkinson' disease, in multiples sclerosis or of essential tremor (n=4),[@R13] atrial fibrillation (n=3),[@R14] rheumatoid arthritis (n=3),[@R33] wet age-related macular degeneration and diabetic retinopathy (n=3),[@R2] multiples sclerosis (n=1),[@R25] cataract (n=1)[@R40] and falling in patients with stroke  (n=1).[@R20] The studies altogether involved 1048 subjects, 758 subjects with the target condition and 290 healthy volunteers or controls. One paper reported on approximately 3000 skin lesions of an unknown number of patients.[@R28] The complete data abstraction of these studies is available in the online [supplementary appendix 2](#SP2){ref-type="supplementary-material"}.

Eleven studies[@R11] that investigated 13 diagnostic health apps allowing the construction of 17 two-by-two tables qualified for the meta-analysis. Twelve tables reported on diagnosis of melanoma, three on Parkinson's disease, one assessed falling in patients with chronic stroke and another atrial fibrillation.

Methodological quality {#s3c}
----------------------

A summary of the methodological quality is shown in [table 2](#T2){ref-type="table"}.

###### 

Summary of methodological quality assessed with the QUADAS-2[@R22]

  First  author's  name and  year of publication   QUADAS-2: patient selection   QUADAS-2: index test   QUADAS-2: reference standard   QUADAS-2: flow and timing
  ------------------------------------------------ ----------------------------- ---------------------- ------------------------------ ---------------------------
  Arora *et al*[@R21] 2014                         Yes                           Yes                    Yes                            Yes
  Arora *et al*[@R11] 2015                         Yes                           Yes                    No                             Yes
  Chadwick *et al*[@R12] 2014                      Yes                           Yes                    No                             Yes
  Kostikis *et al*[@R13] 2015                      Yes                           Yes                    No                             Yes
  Lagido *et al*[@R14] 2014                        Yes                           Yes                    Yes                            Yes
  Maier *et al*[@R15] 2015                         Yes                           Yes                    No                             Yes
  Ramlakhan *et al*[@R16] 2011                     Yes                           Yes                    Yes                            Yes
  Takuya *et al*[@R20] 2015                        Yes                           Yes                    Yes                            Yes
  Wadhawan *et al*[@R18] 2011                      Yes                           Yes                    No                             Yes
  Wadhawan *et al*[@R18] 2011                      Yes                           Yes                    Yes                            Yes
  Wolf *et al*[@R19] 2013                          Yes                           Yes                    Yes                            Yes

QUADAS, Quality Assessment of Diagnostic Accuracy Studies.

Ten studies had a diagnostic case--control design and one was a prospective cohort study.[@R14] Only in one paper, patients were sampled in a consecutive manner.[@R15]

A high risk of bias was assessed in all cases. Most high-risk ratings were assigned in domains of 'Patient Selection', 'Index Test' and 'Flow and Timing', whereas fewest high-risk ratings were found within the domain of the 'Reference Standard'. Hence, several sources of bias were identified that may have affected study estimates. Methodological criteria that were frequently inadequately addressed were 'interpretation of reference standard without knowledge of the index test' and vice versa.

Usability {#s4}
=========

Only four studies assessed usability of the investigated diagnostic health app.[@R2] None used a validated instrument. Questions on usability involved that is, reasons for non-adherence, simplicity of use and difficulties and comprehensibility.

Exploratory analyses of diagnostic accuracy {#s4a}
-------------------------------------------

The summary estimate for sensitivity was 82% (95% CI; 0.56 to 0.94) and pooled specificity was 89% (95% CI 0.70 to 0.97). In a subgroup analysis of 12 reports, pooled sensitivity of studies assessing melanoma was 0.73 (95%CI 0.36 to 0.93) and pooled specificity was 0.84 (95% CI 0.54 to 0.96). No pooling was possible for Parkinson's disease, falling in patients with chronic stroke and atrial fibrillation due to the limited number of studies.

Only one of the apps assessed in this review was available on Apple's or Google's app stores.[@R12] A summary of test performance characteristics is shown in [table 3](#T3){ref-type="table"} and the hierarchical summary receiver operating characteristic curve is seen in [figure 2](#F2){ref-type="fig"}.

###### 

Test performance characteristics

  First author's name and year of publication   Sensitivity (%)   Specificity (%)   TP   FP   FN   TN    AUC            Application's name   Target disease
  --------------------------------------------- ----------------- ----------------- ---- ---- ---- ----- -------------- -------------------- -----------------------------------------
  Arora *et al*[@R21] 2014                      100.0             100.0             10   0    0    10    Not reported   Not reported         Parkinson's disease
  Arora *et al*[@R11] 2015                      100.0             100.0             10   0    0    10    Not reported   Not reported         Parkinson's disease
  Chadwick *et al*[@R12] 2014                   0.0               100.0             0    0    5    10    Not reported   Skin Scan            Melanoma
  Chadwick *et al*[@R12] 2014                   0.0               100.0             0    0    4    5     Not reported   Mel App              Melanoma
  Chadwick *et al*[@R12] 2014                   80.0              20.0              4    8    1    2     Not reported   Mole Detective       Melanoma
  Chadwick *et al*[@R12] 2014                   80.0              60.0              4    4    1    6     Not reported   SpotMole Plus        Melanoma
  Chadwick *et al*[@R12] 2014                   80.0              60.0              4    4    1    6     Not reported   Dr Mole Premium      Melanoma
  Kostikis *et al*[@R13] 2015                   82.6              90.0              19   2    4    18    0.94           Not reported         Parkinson's disease
  Lagido *et al*[@R14] 2014                     75.0              97.1              6    1    2    34    Not reported   Not reported         Atrial fibrillation
  Maier *et al*[@R15] 2014                      73.1              83.1              19   20   7    98    Not reported   Not reported         Melanoma
  Ramlakhan *et al*[@R16] 2011                  91.3              48.6              42   19   4    18    Not reported   Not reported         Melanoma
  Takuya *et al*[@R20] 2015                     72.7              84.6              8    2    3    11    0.75           Not reported         Falling in patients with chronic stroke
  Wadhawan *et al*[@R17] 2011                   81.1              86.2              30   12   7    75    0.91           Skin scan            Melanoma
  Wadhawan *et al*[@R18] 2011                   87.3              71.3              96   68   14   169   Not reported   7-point checklist    Melanoma
  Wolf *et al*[@R19] 2013                       70.0              39.3              42   74   18   48    Not reported   Not reported         Melanoma
  Wolf *et al*[@R19] 2013                       68.3              36.8              41   79   19   46    Not reported   Not reported         Melanoma
  Wolf *et al*[@R19] 2013                       6.7               93.6              4    7    56   103   Not reported   Not reported         Melanoma

AUC, area under the curve; FN, False Negative; FP, False Positive; TN, True Negative; TP, True Positive.

![Hierarchical summary receiver operating characteristic curve (HSROC).](bmjopen-2017-018280f02){#F2}

Discussion {#s5}
==========

Main findings {#s5a}
-------------

This systematic review of studies assessing the performance of diagnostic health apps using smartphone sensors showed that scientific evidence is scarce. Available studies were small and had low methodological quality. Only one-third of available reports assessed parameters of diagnostic accuracy. Only one app included in the meta-analysis is currently available on app stores. The large majority of health apps available in the stores have not undergone a solid scientific enquiry prior to dissemination.

Results in light of existing literature {#s5b}
---------------------------------------

To the best of our knowledge, this is the first systematic review assembling the evidence of diagnostic mobile health apps in a broader context. We are aware of one recent paper by Donker and coworkers, who systematically summarised the efficacy of mental health apps for mobile devices.[@R43] In line with our findings, Donker and colleagues call for further research into evidence-based mental health apps and for a discussion about the regulation of this industry. Other reviews, examining efficacy and effectiveness of mobile health apps support our findings.[@R7] For example, Bakker and colleagues called for randomised controlled trials to validate mental mobile health apps in clinical care.[@R8] Likewise, Majeed-Ariss and coauthors, who systematically investigated mobile health apps in chronically ill adolescents, pointed at the need of scientific evaluation involving healthcare providers' input at all developmental stages.[@R7]

Strength and limitations {#s5c}
------------------------

We conducted a comprehensive literature search to retrieve the published evidence, applied stringent inclusion criteria and assessed the methodological quality of the studies systematically. We applied an overinclusive definition of diagnosis, because for example, symptom monitoring might contribute in the diagnostic work-up of a patient. Out of the papers qualifying for inclusion into this review, only about 25% investigated the diagnostic accuracy of the app. We believe that a broader concept of diagnosis in this particular context was useful to capture the relevant literature. Our study has several limitations. First, the primary studies were found to have low methodological quality and level of reporting. All but one of included studies used diagnostic case--control designs. While this design might be helpful in early evaluation of diagnostic tests, it usually leads to higher test performance characteristics than could be expected in clinical practice. From that viewpoint, the summary estimates from the exploratory meta-analysis need to be interpreted very cautiously. The searches performed in the electronic databases had low specificity leading to a large number of irrelevant records. Correspondingly, the 'number needed to read' was very high.[@R44] Although we assessed the records in duplicate by two experienced systematic reviewers, we cannot fully rule out that we missed potentially relevant articles. Finally, we were unable to test all but one of the apps[@R12] that had been assessed in this review, because they were not available anymore, and thus lack first-hand experience.

Implications for research {#s5d}
-------------------------

Led by the consumer electronics industry, the production of mobile health apps has gained in importance and popularity within recent years. Unfortunately, the scientific work-up of the clinical usefulness of these apps is leaping behind. While many studies have highlighted the potential and possible clinical usefulness of health apps, research conducted according to the well-established standards of design, sampling and analysis are missing. The regulation applied in the USA, the EU and other countries does not go far enough. Ensuring that medical health apps meet criteria on technical concerns is only one important element of regulation. From the consumers or patients' perspective, a trustworthy source showing the amount and level of scientific data underpinning the claims made in the app descriptions would be very useful. In our view, it is very important that technical, clinical and methodological experts jointly form an interdisciplinary development team. While the IT experts take care of the technical developments, data safety and compliance with regulatory requirement, clinical expert certify that the app addresses the right medical context, and researchers finally impose appropriate scientific methods to validly quantify the clinical yield. We believe that developers of a (diagnostic) mobile health app should adopt the same hierarchical framework that has been proposed for imaging testing in the seminal paper of Fryback and Thornbury.[@R45]

Conclusion {#s6}
==========

In this comprehensive systematic review, we found a lack of scientific evidence quantifying the diagnostic value of health apps in the medical literature. The information about the diagnostic accuracy of currently available health apps on Apple's and Google's app stores is almost absent. Consumers and healthcare professionals should be aware of this when using or recommending them.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

RB and LF contributed equally.

**Contributors:** RB, LF, LMB, KRL, NSB and MAT obtained and appraised data. LMB and MKS wrote the paper with considerable input from OJ, MAT, RB and KRL. All coauthors provided intellectual input and approved the final manuscript. LMB was responsible for the design and the statistical analysis of the study and is the study guarantor.

**Funding:** The work presented in this paper was funded by Medignition Inc, a privately owned company in Switzerland providing health technology assessments for the public and private sectors, via an unrestricted research grant.

**Competing interests:** LMB holds shares of Medignition.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** The dataset containing all abstracted data of included studies is available from the Dryad repository: doi:10.5061/dryad.900f8.
